About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, October 27th, 2014

The QualityStocks
Daily Stock List



BUYINS.NET, Greenbackers, OTCPicks, Stock Guru, and Real Pennies reported earlier on PAID, Inc. (PAYD), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

PAID, Inc. offers turnkey online tools and services, which enable its customers to customize a solution that is right for them. The OTCQB-listed Company offers AuctionInc™ online shipping calculation and shopping cart software employing its patented technology to streamline ecommerce. Founded in 1999, PAID is headquartered in Westborough, Massachusetts.

PAID was established focusing on web-development and online auctions. The Company offers entertainers and businesses total web-presence and related services. PAID supports and manages clients’ official websites and fan-community services. This includes e-commerce, VIP ticketing, live event fan experiences, user-generated content, client content publishing and distribution, fan forums, social network management, social media marketing, customer data capture, management and analysis.

The Company created the above-mentioned proprietary service AuctionInc™. This is a suite of online shipping and tax management tools. They provide accurate shipping and tax calculations and packaging algorithms, which provide customers with the best possible shipping and tax solutions. The product is modular based.

PAID filed for a patent before introducing it to the public in April of 2002. PAID obtained its first patent on the shipping calculator in January of 2008. It obtained the second patent in April of 2011, the third patent in January of 2013, and the fourth patent in August of 2013.

This past January, PAID announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,635,150 to PAID on January 22, 2014. The patent adds to the Company’s existing patent portfolio that includes patent numbers 8,521,642, 8,352,357, 7,930,237, 7,324,968 titled "Method and System for Improved Online Auction." All of these patents relate to the real-time calculation of shipping, insurance, and taxes online.

PAID continues to concentrate the Company’s resources on further developing and upgrading its AuctionInc ShopCart with its Integrated Shipping Calculator and its new website www.shippingcalc.com. This site permits Auction and E-commerce companies to integrate PAID’s shipping solutions into their platforms.

PAID, Inc. (PAYD), closed Monday's trading session at $0.065, down 5.25%, on 194,742 volume with 20 trades. The average volume for the last 60 days is 374,737 and the stock's 52-week low/high is $0.038/$0.26.

Cloud Medical Doctor Software Corp. (NSCT)

PennyStocks24, Stock Legends, OTCMagic, PREPUMP STOCKS, Penny Stock Newsletter, Damn Good Penny Picks, Penny Picks, OtcShortReport, Pennystocktweeters.com, Stock Twiter, Impressive Penny Stocks, and Winston Small Cap reported recently on Cloud Medical Doctor Software Corp. (NSCT), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Cloud Medical Doctor Software Corp. (Cloud-MD) is a leading provider of "Cloud Based" Medical Practice Management Business solutions and a provider of Digital Electronic Security (DES) solutions. The design of the Company’s solutions are by doctors for doctors. Cloud-MD has three goals: increasing individual practice income; creating personal investment value; and regaining influence over the way medicine is practiced and administrated. Cloud-MD has its headquarters in Henderson, Nevada.

Cloud-MD has a fully integrated and interoperable suite of Software-as-a-Service (SaaS) products and medical practice services. These provide the foundation for its Revenue Cycle Management capabilities. Additionally, the Company provides the installation, training, and support of these systems.

Cloud-MD offers a complete collection of integrated Practice Management (PM), Revenue Management (RM), Patient Profile Management (PPM), and Medical Billing Services (PBS) solutions. These meet all of the major requirements of healthcare providers. Cloud-MD has more than three decades of billing experience and over $1 billion in medical claims processed.

This past July, Cloud-MD announced that its soon-to-be-released Cloud+MD Office 2.0 will receive industry Meaningful Use Stage 2 (MU2) certification. Cloud+MD Office 2.0 is a "Cloud Based", fully integrated and interoperable suite of medical software and services. The design of it is by experienced healthcare analysts and programmers for healthcare providers, which produces "Actionable Information" to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems and Billing Services optimize a wide variety of business processes. The MU2 final rules define a common dataset for all summary of care records. This includes an impressive array of structured and coded data to be formatted uniformly and sent securely during transitions of care.

In August, Cloud-MD announced that its Cloud-MD V4.1 EHR Module was certified as a Complete Ambulatory 2014 Meaningful Use both Stage 1 and Stage 2 EMR under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Certification Body (ONC-ACB) program.

Last month, CipherShop, a division of Cloud-MD, announced that CipherLoc® polymorphic cipher engine completed Phase I development. It is moving in to Phase II Silo development. CipherLoc's capabilities can now be demonstrated, using live data on how CipherLoc's polymorphic cipher engine can protect data from being hacked.

Cloud Medical Doctor Software Corp. (NSCT), closed Monday's trading session at $0.022, even for the day, on 638,200 volume with 19 trades. The average volume for the last 60 days is 877,330 and the stock's 52-week low/high is $0.011/$0.10.

Baltia Air Lines, Inc. (BLTA)

PennyStocks Forever, PennyStocks24, StockHideout, Stock Roach, PennyStockSpy, 007 Stock Chat, Undiscovered Equities, MicrocapVoice and THEOTCBBLIST reported on Baltia Air Lines, Inc. (BLTA), and today we also report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed Baltia Air Lines, Inc. is a U.S. start-up airline. The Company’s service is subject to receipt of government operating authority, and as such, no ticket sales are currently available. Baltia Air Lines is the only Part 121 (heavy jet operator) start-up airline in the U.S. today that has received Government fitness approval. Baltia is preparing to operate the only non-stop flights for passengers, cargo, and mail from New York's JFK International Airport to Pulkovo Airport in St. Petersburg, Russia. The Company is based at John F. Kennedy International Airport, Jamaica, New York.

Baltia Air Lines has its office/base of operations at Willow Run Airport in Ypsilanti, Michigan. This location will serve as its operations control center. At the Ypsilanti location, an aircraft maintenance contractor will complete major aircraft maintenance on a contract basis.

Baltia’s plan is to provide First, Business, and Voyager Class accommodations. Baltia’s intention is to provide this high quality three-class passenger service, and reliable cargo and mail transportation. The Company’s aim is to become the top U.S. airline in the trans-Atlantic market between the major U.S. cities and capital cities of Eastern Europe. This includes Russia, Latvia, Ukraine, and Belarus.
Baltia’s plan is to commence its foreign scheduled air transportation as the only U.S. airline, connecting directly, to two of the world's most prominent cities - New York, New York and St. Petersburg, Russia. Baltia has identified many market segments in the U.S.-Russia market. These are Business Travelers, General Tourism, Ethnic Travelers, Special Interest Groups, Professional Exchanges, and Government and Diplomatic Travel. The Company has passenger service and ground service arrangements at JFK and at Pulkovo Airport in St. Petersburg.

At present, Baltia is in an advanced stage of the FAA Air Carrier Certification process. The Company expects to start revenue generating flights this year. Baltia Air Lines announced this past summer that training of its initial corps of stewards was completed on July 29, 2014. Furthermore, it announced that training of its initial corps of pilots/check airmen was completed on July 30, 2014.

Earlier, this month, the Company announced that it entered into Phase III of the FAA Air Carrier Certification. Phase III consists of the Table Top Exercise, Mini-Evacuation Demonstration, as well as Proving Flights (overall, the Performance Assessment Phase).

Last month, Baltia Air Lines announced that the C4 Check of its B747 Aircraft was signed off by Kalitta Maintenance. The C4 check (also called a D Check) is the most complete inspection that an airliner undergoes. This check takes place every six years. The inspection involves structural and systems testing using X-ray, ultrasound, and other methods.

Baltia Air Lines, Inc. (BLTA), closed Monday's trading session at $0.0176, down 4.35%, on 5,040,019 volume with 96 trades. The average volume for the last 60 days is 3,303,938 and the stock's 52-week low/high is $0.008/$0.041.

Amarantus Bioscience Holdings, Inc. (AMBS)

Streetwise Reports, PennyStocks24, Pumps and Dumps, Pennybuster, SmallCapVoice, and SuperNova Elite reported on Amarantus Bioscience Holdings, Inc. (AMBS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

San Francisco, California headquartered Amarantus Bioscience Holdings, Inc. is a biotechnology company concentrating on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis. The Company is developing certain biologics surrounding the intellectual property (IP) and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive global license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease. Amarantus Bioscience lists on the OTC Market’s OTCQB.

Additionally, Amarantus has licensed Eltoprazine, a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. Moreover, the Company owns the IP rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). It is developing MANF-based products as treatments for brain disorders. Its lead therapeutic program MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a wide array of devastating human disorders.

Amarantus also owns IP for the diagnosis of Parkinson's disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard). The Company is a Founding Member of the Coalition for Concussion Treatment (#C4CT). This movement started in collaboration with Brewer Sports International (BSI). It is working to raise awareness of new treatments in development for concussions and nervous-system disorders.

This month, Amarantus announced that it applied to the US Food & Drug Administration (FDA) for Orphan Drug Designation for MANF in retinitis pigmentosa (RP). MANF was discovered using the Company’s proprietary PhenoGuard Protein Discovery Engine. The Company owns all the intellectual property.

The FDA Orphan Drug Designation program provides a special status to drugs and biologics intended to treat, diagnose or prevent so-called orphan diseases and disorders that affect less than 200,000 people in the United States. Retinitis pigmentosa (RP) refers to a group of inherited diseases causing retinal degeneration frequently leading to blindness.

Today, Amarantus published a new blog post on The Chairman’s Blog, written by the Company’s Chief Executive Officer, Mr. Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication. It enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus Bioscience Holdings, Inc. (AMBS), closed Monday's trading session at $0.084, down 2.33%, on 2,252,749 volume with 166 trades. The average volume for the last 60 days is 5,117,525 and the stock's 52-week low/high is $0.0391/$0.196.

Telupay International, Inc. (TLPY)

Ascending Stocks, Penny Stocks Profile, Value Penny Stocks, and Penny Picks reported today on Telupay International, Inc. (TLPY), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Telupay International, Inc. is the parent company of the TelUPay Group, which has developed the next generation of secure mobile banking and payments technology. The design of it is for banks, mobile operators (MNOs), money transfer operators (MTOs), payment processors, retailers/merchants, credit card companies, microfinance, large corporations and other financial institutions. Telupay’s shares trade on the OTCQB.

TelUPay offers customized services and continuously develops new applications. Its mWallet is a stand-alone, server-side, mobile account technology. It is specifically designed for Mobile Operators, Money Transfer Operators and other large network operators. TelUPay’s mPOS mobile payment solutions equip merchants to accept mobile payments.

The Company’s Mobile ATM (ATM Lite) allows consumers to have all the facilities of an ATM service. Registration with the user's bank enables the consumer to pre-authorize an amount of money to be available to spend. Regarding Its ATM API, TelUPay's portfolio of its 4th Generation technology is an ATM enabling technology. It takes advantage of banks existing global investments in ATM networks to complement them.

The Company’s bank-grade mobile banking and payment service uses the most secure encryption technology available today for the bank and the end-user. Its mobile service includes transfers between accounts, peer-to-peer fund transfers (remittances) domestically and globally, bill payments, merchant payments, mobile airtime purchases, balance inquiries, mPOS transactions, both Card Present and Card Not Present, and numerous other services.

At the beginning of October, TelUPay International announced that it, through its Philippine subsidiary, TelUPay (Philippines), Inc. and its partnership with Megalink, delivered a secure mobile banking and payment services to MASS-SPECC COOPERATIVE DEVELOPMENT CENTER (MASS-SPECC), a member of Megalink. TelUPay (Philippines) and MASS-SPECC signed a Letter of Understanding (LOU) launching an incentive marketing campaign targeted to promote and engage MASS-SPECC member-cooperatives and its leaders to use the TelUPay mobile banking and payment services.

In addition, this month, TelUPay International announced that it, through TelUPay (Philippines), delivered a secure mobile payment platform and signed a 5-year service agreement with 1Bro. 1Bro is one of the larger agent networks in the Philippines.

Today, TelUPay International announced that it, through its Dubai subsidiary, TelUPay (M.E) FZE, successfully completed its pilot program testing its secure, electronic, Prepaid Mobile Airtime system servicing the Micronesia region. Celluserv uses TelUPay's PIN distribution system with a direct interface to Mobile Network Operator (MNOs) systems, to electronically distribute prepaid mobile airtime.

Telupay International, Inc. (TLPY), closed Monday's trading session at $0.37, up 23.33%, on 504,256 volume with 240 trades. The average volume for the last 60 days is 12,983 and the stock's 52-week low/high is $0.30/$0.65.

Cocrystal Pharma, Inc. (COCP)

PennyStocks Forever reported earlier on Cocrystal Pharma, Inc. (COCP), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Cocrystal Pharma, Inc. is a biotechnology company developing new antiviral therapeutics for human diseases. The Company merged this year with Biozone Pharmaceuticals, Inc. (originally announced on January 3, 2014). Cocrystal Pharma lists on the OTC Markets’ OTCQB. The Company has its corporate headquarters in
Bothell, Washington.

Cocrystal Pharma has earlier received strategic investments from Teva Pharmaceuticals, OPKO Health (OPK) and The Frost Group. OPKO Health and The Frost Group together own around 48 percent of Cocrystal Pharma.

Cocrystal Pharma focuses on the discovery and development of novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. It utilizes unique technologies and Nobel Prize winning expertise to create first- and best-in-class antivirals. The design of these technologies and its market-focused approach to drug discovery are to efficiently deliver small molecule therapeutics that are safe, effective, as well as convenient to administer.  

Cocrystal Pharma now has five therapeutic programs targeting the Hepatitis C Virus (HCV), Influenza Virus, the Human Rhinovirus (HRV), Dengue Virus, and the Norovirus. It is targeting two Hepatitis C replication enzymes with its Polymerase program at lead optimization stage and its Helicase program at lead identification stage. Its Influenza, HRV, Dengue, and Norovirus programs are targeting unmet multi-billion dollar market opportunities with first-in-class antivirals. 

Cocrystal is developing drug candidates specifically designed to be effective against all strains of the influenza virus and to have a high barrier to resistance. Selection of a lead compound for clinical development is planned to take place by early 2015. Regulatory filings to begin clinical studies for influenza are planned for December 2015.

In Q2 2014, Cocrystal Pharma completed consolidation of its Mountain View, California operations into its Bothell, Washington location. This is for better synergies among the programs and cost efficiencies. In addition, in Q2, its Hepatitis C program continued to make progress. The Company has selected CDI-244 for development as a treatment for patients with Hepatitis C (HCV). Cocrystal plans regulatory filings to start clinical trials of CDI-244 in early 2015.

Furthermore, Company scientists have made first-rate progress discovering potent inhibitors of the influenza endonuclease, an enzyme which is essential for viral genome replication. Selection of a lead compound for clinical development is planned to take place by early 2015. Regulatory filings to start clinical studies for influenza are planned for December 2015.

Last week, Cocrystal Pharma reported that it has developed what the Company believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product. Cocrystal Pharma employed its core platform technology to develop the in vitro test.

Cocrystal Pharma, Inc. (COCP), closed Monday's trading session at $0.487, down 8.11%, on 706,433 volume with 203 trades. The average volume for the last 60 days is 363,678 and the stock's 52-week low/high is $0.23/$0.847.

Bioheart, Inc. (BHRT)

Energy and Capital and SmallCapVoice reported earlier on Bioheart, Inc. (BHRT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bioheart, Inc.’s dedication is to maintaining its leading position within the cardiovascular sector of the cell technology industry. The OTCQB-listed Company delivers cell therapies and biologics. These help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions, as well as other issues. Its lead product is MyoCell®. Bioheart has its headquarters in Sunrise, Florida.

The Company’s objectives are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and lessen health care costs and hospitalizations. Regarding biotechnology, Bioheart is concentrating on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease.

Bioheart’s MyoCell® product is a clinical muscle-derived cell therapy. The design of it is to populate regions of scar tissue within a patient's heart with new living cells to improve cardiac function in chronic heart failure patients. The Company’s MyoCell® therapy consists of myoblasts, which are injected into the scar tissue that has formed in the hearts of patients suffering from heart failure. The increased muscle formed by MyoCell® in these patients’ hearts has been shown to lead to improved cardiac function and an improved quality of life. MyoCell® may help to promote myogenesis or new muscle formation.

This past May, Bioheart announced an update on the Phase I safety trial using adipose derived cells. The Company’s AdipoCell™ product is presently undergoing study in an assortment of indications. These include erectile dysfunction, chronic obstructive pulmonary disease and dry macular degeneration. Approximately four years ago, Bioheart started a study using adipose derived stem cells (AdipoCell™) in congestive heart failure patients. The patients were contacted earlier to assess quality of life. The patients reported that they are in good spirits and doing well. AdipoCell™ may help to promote angiogenesis or new blood vessel formation in ischemic tissue.

In September, Bioheart announced a successful grand opening of the laboratory and clinic in South Africa. The new facility, called South African Stem Cell Institute (SASCI), immediately began treating patients.

This month, Bioheart released preliminary 12 month data from its Phase I ANGEL Trial. Fully funded by Bioheart, the trial is taking place in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). The Phase I study will provide necessary safety and preliminary efficacy of adipose derived stem cells (AdipoCell™) in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.

Additionally, this month, Bioheart announced a partnership to bring Bioheart regenerative therapies to Colombia. The Company and Global Stem Cells Group, Inc. have partnered with Stemlab to introduce regenerative medicine to the 48+ million people living in Colombia.

Bioheart, Inc. (BHRT), closed Monday's trading session at $0.0205, up 28.12%, on 6,631,588 volume with 201 trades. The average volume for the last 60 days is 935,814 and the stock's 52-week low/high is $0.0063/$0.08.


The QualityStocks
Company Corner


Zenosense, Inc. (ZENO)

The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.405, up 1.25%, on 48,520 volume with 34 trades. The stock’s average daily volume over the past 60 days is 86,649, and its 52-week low/high is $0.15/$1.00.

Zenosense, Inc. was pleased to announce considerable progress made in the development of its MRSA/SA detector todaty. The prototype device successfully achieved a sensibility detection rate greater than 95% on cultured headspace in a series of tests over a two week period in a clinical setting.

Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.

Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.

The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer

Zenosense, Inc. Company Blog

Zenosense, Inc. News:

Zenosense, Inc.; MRSA/SA Prototype Achieves over 95% Sensibility in Cultured Headspace

Zenosense, Inc.; Protocol Design -- Lung Cancer Detection Tests

Zenosense, Inc. Update -- MRSA and Lung Cancer Device Development

One World Holdings, Inc. (OWOO)

The QualityStocks Daily Newsletter would like to spotlight One World Holdings, Inc. (OWOO). Today, One World Holdings, Inc. closed trading at $0.0082, up 2.50%, on 1,507,691 volume with 15 trades. The stock’s average daily volume over the past 60 days is 551,708, and its 52-week low/high is $0.0033/$2.8462.

One World Holdings, Inc. (OWOO) subsidiary, The One World Doll Project, was established in 2010 to make a significant positive cultural impact through the doll category, transcending global and ethnic borders to create positive self-image in young women and girl around the world. Led by worldwide famous doll designer Stacy McBride-Irby, The One World Doll Project team has more than 50 collective years in the doll and toy industry and is dedicated and armed with the experience to ensure that the dolls are of the highest quality and value.

In 2013, the company released its Prettie Girls!™ line of multi-cultural fashion dolls uniquely designed with individual physical attributes, personal stories and hobbies, and goals and inspirations. For young girls, the dolls are a friend, a partner in play, and a glimpse of their biggest, brightest dreams. For young women, the dolls are a symbol of who they are and what they can achieve. For doll connoisseurs, The One World Doll Project promises stylish works of art that will become a vital part of a growing collectors’ market.

The One World Doll Project also has a Signature Celebrity Collection of Prettie Girls! and in 2013 released its first celebrity collectors doll modeled after supermodel Cynthia Bailey from The Real Housewives of Atlanta. Since the release of the doll, it has been showcased with Synthia on The Arsenio Hall Show, What Happens Live with Andy Cohen and The Bethenny Show.

Using a web-based sales model, One World Holdings plans to quickly capture significant market share in the dolls and stuffed toys space. After securing a strong online presence, the company will focus on brick and mortar retailing as it moves toward the ultimate pursuit of expanding worldwide. The company has established distribution deals with Toys “R” Us, HEB, dollgenie.com, Tuckers Toy Shop, pattycakedoll.com, and has recently expanded its retail presence internationally with the People’s Pharmacy storechain in the Central American country of Belize. The Prettie Girls! Dolls have been featured in national and international media spotlights like CNN, The Wall Street Journal, Jet Magazine, Bloomberg.com, Parade.com, Dolls Magazine, The Toy Book, The Houston Chronicle and Houston Business Journal, and TheStreet.com. Disclaimer

One World Holdings, Inc. Company Blog

One World Holdings, Inc. News:

The One World Doll Project Announces Financing Relationship With New York Hedge Fund, Blackbridge Capital

One World Holdings, Inc. Announces Engagement of QualityStocks Investor Relations Services

The One World Doll Project Announces New Online Distribution With Toys"R"UsŪ

Pan Global Corp. (PGLO)

The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.0224, up 12.00%, on 77,018 volume with 6 trades. The stock’s average daily volume over the past 60 days is 537,503, and its 52-week low/high is $0.009/$0.96.

Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.

The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.

Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.

Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer

Pan Global Corp. Company Blog

Pan Global Corp. News:

Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017

Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India

Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India

Cleartronic, Inc. (CLRI)

The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.10, even for the day. The stock’s average daily volume over the past 60 days is 8,126, and its 52-week low/high is $0.04/$0.5499.

Consorteum Holdings, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.

VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.

A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.

Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer

Cleartronic, Inc. Company Blog

Consorteum Holdings, Inc. News:

Cleartronic, Inc. (CLRI) Announces Capitalization Benefit Plan and Expansion of Board of Directors

Cleartronic Announces License Agreement With Collabria LLC

Cleartronic, Inc. (CLRI) Developing 'Capitalization Benefit Plan'

Sibling Group Holdings, Inc. (SIBE)

The QualityStocks Daily Newsletter would like to spotlight Sibling Group Holdings, Inc. (SIBE). Today, Sibling Group Holdings, Inc. closed trading at $0.147, off by 1.28%, on 42,739 volume with 8 trades. The stock’s average daily volume over the past 60 days is 43,869, and its 52-week low/high is $0.04/$0.24.

Sibling Group Holdings, Inc. (SIBE) is enhancing and delivering 21st century learning with advanced technology and education management operations. Accessing funds from the public capital markets is part of the company’s unified strategy to accelerate the improvement of Pre-K, K-12 and post-secondary education around the world. Better educated children and adults, sustainable and cost effective instructional models, and reduced dependence on governmental funding are the end results.

Existing offerings include professional development for the teaching profession; educational technology, including classroom management tools; a comprehensive and flexible online curriculum; an aggregation platform for massive open online courses, and academic and skills credentialing. Investments are being made in specialized curriculum such as STEM (science, technology, engineering and math), ESL (english as a second language), SEL (social and emotional learning), and Special Ed aimed at supporting students with special needs and their teachers.

Sibling Group is acquiring various Ed-tech businesses and components with the goal of building the first complete solution for the delivery and management of educational content, and tracking educational results, in the digital media – from curriculum to course certification. The recent acquisition of Blended Schools Network (BSN), which serves over 160 school districts with 300,000 course enrollments and currently offers 212 different online courses, is a great example and has provided Sibling Group with extensive infrastructure and solid groundwork for growth in a rapidly growing industry.

IBIS Capital is forecasting fifteen-fold growth in the e-learning market over the next 10 years and has even suggested that under certain circumstances the transition to digital education may be quicker and more disruptive than ever observed in the media industry. With a strong, highly experienced management team, Sibling Group is in a unique position to continue expanding its portfolio through additional acquisitions and fundamental growth. Disclaimer

Sibling Group Holdings, Inc. Company Blog

Sibling Group Holdings, Inc. News:

Sibling's Blended Schools Network and LoudCloud Team Up to Accelerate Online Learning

Sibling Group Holdings, Inc. President David Saba, to Be Interviewed LIVE on Clear Channel Business Talk Radio -- (September 30, 2014)

Sibling's Blended Schools Network Division Offers Special Education Professional Development for All Educators

Alliance Creative Group (ACGX)

The QualityStocks Daily Newsletter would like to spotlight Alliance Creative Group (ACGX). Today, Alliance Creative Group closed trading at $0.0022, off by 4.35%, on 5,945,300 volume with 15 trades. The stock’s average daily volume over the past 60 days is 4,033,564, and its 52-week low/high is $0.0007/$0.011.

Alliance Creative Group (ACGX), launched in 2000 as an online marketing company, today operates four key business units pooled together as a strong and profitable source for customized plans and projects for clients spanning multiple industries. The company's key services include creative and design, printing and packaging, direct mailing, product development, supply chain management, project management, event marketing, business consulting and strategic marketing.

Alliance Creative maintains and operates two company websites: alliancecreativegroup.com and Print4aCause.com. Always on the prowl for advancement, the company is also currently in discussions with multiple parties regarding potential mergers or acquisitions, and exploring other equipment and software upgrade options. Additionally, Alliance Creative is seeking a funding partner to help create and accelerate its bigger roll-up business model.

The company’s overarching long-term vision is to create a one-stop-shop printing and packaging company powered by synchronized business divisions with a shared vision to increase overall revenues and profits. This business model leverages vertical integration and cross-promotion between various company sectors and allows Alliance Creative to share resources and maximize efficiencies. These components also improve buying power for the corporation and increase value for both clients and shareholders.

Alliance Creative’s management team boasts decades of production and creative experience that guide company along its trek to generate sales revenue and profits and create a high quality customer experience. Under current management, Alliance Creative in the last three years has recorded more than $30 million in total revenue; $2 million in net income; and has $6 million in total assets in the books. Disclaimer

Alliance Creative Group Company Blog

Alliance Creative Group News:

Alliance Creative Group Has Been Awarded Additional Printing and Packaging Business From John Paul Mitchell Systems for Their PM Shines Line

Alliance Creative Group (ACGX) Unveils High-End, Branded Gift Box Website to Help Clients Give a Gift and Support a Cause

Paul Sorkin COO of Alliance Creative Group (ACGX) Talks to TheStockRadio.com About Record Revenues, Recent Agreements and Planned Growth

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH). Today, Consorteum Holdings, Inc. closed trading at $0.005, even with yesterday's close, on 13,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 209,406, and its 52-week low/high is $0.0031/$0.02.

Consorteum Holdings, Inc. (CSRH) has spent the last 3 years developing relationships and licensing agreements to take the center stage in the emerging market of mobile gaming. The company has the capability to deliver rich mobile content to end users who will use their smart phones in ways that could not even have been imagined five years ago.

Specializing in delivery of mobile content, mobile payment solutions and products through a mix of on-deck partnerships, license agreements, and joint venture revenue share arrangements, the company operates as a technology and services aggregator to meet the diverse needs of its client base. This approach enables unparalleled flexibility when sourcing solutions, resulting in smarter, faster deployment of technologies, competitive pricing, and potential for new streams of revenue.

ThreeFiftyNine Inc., a wholly owned subsidiary, hired a software development team that had previously designed the world’s first regulatory compliant mobile platform for delivery of gaming content created by a third party. The platform, which has met the rigorous standards of the Nevada Gaming Board, the gold standard in regulatory gaming, represents the first generation software delivery platform for mobile devices. The development team spent the past 5 years and millions of dollars in non-recurring engineering costs to complete the development of the platform. At the heart is the capability to deliver any digital content across any cellular network to any mobile device. This key differentiator makes it possible for Consorteum to approach many different markets that are in the business of providing mobile connectivity and mobile content.

Consorteum’s mobile initiatives will benefit multiple business verticals. The company has strategically designed its business initiatives to create repetitive transactions on an ongoing basis. Consorteum's goal is to have their customers think of them more as partners, rather than just technology providers, for longer-lasting, more profitable relationships. Disclaimer

Consorteum Holdings, Inc. Company Blog

Consorteum Holdings, Inc. News:

Consorteum Holdings Signs Mobile Application Development Contract With Bet Butler Limited

Consorteum Holdings Launches New Mobile Results App for Popular Keno Game

Consorteum Holdings Enters Mobile Application Development and Business Agreement With XpertX, Inc.


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters








By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251